Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy

Conner, Joe; Braidwood, Lynne

doi:10.1038/cgt.2012.24

Cited by 17 publications

(12 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ongoing studies in high grade glioma () and solid tumors () will further assess the efficacy of the approach. More recently, additional genetic modifications of HSV‐1716 have incorporated the enzyme nitroreductase (which converts the prodrug CB1954 into an active alkylating agent) (Braidwood et al., 2009) or selected a clone which expresses inhibitor of growth 4 (Ing4) (a tumor suppressor protein) (Conner and Braidwood, 2012) significantly augmenting its oncolytic potency.…”

Section: Introductionmentioning

confidence: 99%

In situ vaccination: Cancer immunotherapy both personalized and off‐the‐shelf

2015

View full text Add to dashboard Cite

As cancer immunotherapy continues to benefit from novel approaches which cut immune 'brake pedals' (e.g. anti-PD1 and anti-CTLA4 antibodies) and push immune cell gas pedals (e.g. IL2, and IFNα) there will be increasing need to develop immune 'steering wheels' such as vaccines to guide the immune system specifically toward tumor associated antigens. Two primary hurdles in cancer vaccines have been: identification of universal antigens to be used in 'off-the-shelf' vaccines for common cancers, and 2) logistical hurdles of ex vivo production of individualized whole tumor cell vaccines. Here we summarize approaches using 'in situ vaccination' in which intratumoral administration of off-the-shelf immunomodulators have been developed to specifically induce (or amplify) T cell responses to each patient's individual tumor. Clinical studies have confirmed the induction of systemic immune and clinical responses to such approaches and preclinical models have suggested ways to further potentiate the translation of in situ vaccine trials for our patients.

show abstract

Section: Introductionmentioning

confidence: 99%

In situ vaccination: Cancer immunotherapy both personalized and off‐the‐shelf

2015

View full text Add to dashboard Cite

show abstract

“…Some groups are focused on isolating the most potent virus (in terms of replication and progeny), while maintaining tumor specificity [67]. Other researchers are arming the viral vectors with neutralizing soluble proteins, which interact with immunosuppressive molecules in the tumor microenvironment and increase tumor cell killing by immune cells [68].…”

Section: Oncolytic Virusesmentioning

confidence: 99%

Immunotherapy for Breast Cancer: Current and Future Strategies

et al. 2017

View full text Add to dashboard Cite

Purpose of Review The breast tumor microenvironment is immunosuppressive and is increasingly recognized to play a significant role in tumorigenesis. A deeper understanding of normal and aberrant interactions between malignant and immune cells has allowed researchers to harness the immune system with novel immunotherapy strategies, many of which have shown promise in breast cancer. This review discusses the application of immunotherapy to the treatment of breast cancer. Recent Findings Both basic science and clinical trial data are rapidly developing in the use of immunotherapy for breast cancer. The current clinical trial landscape includes therapeutic vaccines, immune checkpoint blockade, antibodies, cytokines, and adoptive cell therapy. Summary Despite early failures, the application of immunotherapeutic strategies to the treatment of breast cancer holds promise.

show abstract

“…An oncolytic HSV1716 that expresses ING4 (HSV1716Ing4) showed stronger oncolytic effect than HSV1716, highlighting the potent tumor-destructive ability of ING4 [67]. This anti-proliferation capacity is p53-dependent at least in part.…”

Section: Cell Proliferationmentioning

confidence: 99%

The Emerging Role of Inhibitor of Growth 4 as a Tumor Suppressor in Multiple Human Cancers

Cui

Gao

Zhang

et al. 2015

Cell Physiol Biochem

View full text Add to dashboard Cite

Inhibitor of growth 4 (ING4), a member of the conserved ING family, has been identified as an important tumor suppressor since it plays a critical role in the regulation of chromatin modification, cell proliferation, angiogenesis and cell migration. Some observations suggest that ING4 acts as a key regulator of tumorigenesis through modifying gene transcription in part by regulating the transcription factors p53 and NF-kappaB (NF-κB). However, these models have yet to be substantiated by further investigations. Numerous reports describe the reduced expression of ING4 in cancers, and the responsible mechanisms are involved in gene deletion, mutation, transcriptional and post-transcriptional dysregulation. This review aims to summarize the recent published literature that investigates the role of ING4 in regulating tumorigenesis and progression, and explore its potential for cancer treatment.

show abstract

Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy

Cited by 17 publications

References 43 publications

In situ vaccination: Cancer immunotherapy both personalized and off‐the‐shelf

In situ vaccination: Cancer immunotherapy both personalized and off‐the‐shelf

Immunotherapy for Breast Cancer: Current and Future Strategies

The Emerging Role of Inhibitor of Growth 4 as a Tumor Suppressor in Multiple Human Cancers

Contact Info

Product

Resources

About